A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
| Condition | Carcinoma, Hepatocellular |
|---|---|
| Phase | Phase 2 |
| Sponsor | Jennerex Biotherapeutics |
| Status | Completed |
| Enrollment | 25 participants |
| Interventions | JX-594, Sorafenib |
| Start date | May 26, 2009 |
| Completion date | Sep 27, 2012 |
| Results posted | Jul 14, 2026 |
Summary
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.
Number of Participants With Treatment-Related Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
| JX-594 Followed by Sorafenib | 25 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)